Gefitinib, Trastuzumab, and Docetaxel in Treating Patients With Metastatic Breast Cancer
Status:
Completed
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Gefitinib may stop the growth of tumor cells by blocking the enzymes necessary for
their growth. Monoclonal antibodies such as trastuzumab can locate tumor cells and either
kill them or deliver tumor-killing substances to them without harming normal cells. Drugs
used in chemotherapy, such as docetaxel, work in different ways to stop tumor cells from
dividing so they stop growing or die. Combining gefitinib and trastuzumab with docetaxel may
kill more tumor cells.
PURPOSE: This phase I/II trial is studying the best dose of docetaxel when given together
with gefitinib and trastuzumab in treating patients with metastatic breast cancer.